About Instapill Private Limited
Data last updated: 05 January 2026
Instapill Private Limited is a private limited company based in Bangalore, Karnataka, India, a subsidiary of Tenshi Pharmaceuticals Private Limited. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 02 April 2007, the company has been in operation for over 19 years.
Registered with ROC Bangalore under CIN U24230KA2007PTC042337.
Capital: an authorised share capital of ₹25.58 Cr and a paid-up capital of ₹18.64 Cr. Formerly known as Higher Pharmatech Private Limited and Instapill Private Limited. It is led by directors including Ankit Gupta and Venkataraman Subramanian Iyer.
Last AGM: 16 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No 46 1St Phase Kiadb Industrial Area Harohalli Kanakapura, Bangalore, Karnataka, India – 562112.
As per the financials filed for FY 2025, the company reported a revenue of ₹100.92 Cr, a growth of 11% compared to the previous year.
The company has a workforce of approximately 161 employees as per the latest available data. It operates as a subsidiary of Tenshi Pharmaceuticals Private Limited.
The company is associated with 2 brands - Triphase Pharmaceuticals, Tenshi Life Sciences. As per MCA filings, the company has open charges of ₹232.46 Cr and satisfied charges of ₹190.85 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website tenshi.co.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressPlot No 46 1St Phase Kiadb Industrial Area Harohalli Kanakapura, Bangalore, Karnataka, India – 562112
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Instapill Private Limited
Instapill Private Limited has undergone 2 name changes throughout its history. The company was previously known as Higher Pharmatech Private Limited, and Instapill Private Limited. The current legal name is Instapill Private Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Instapill Private Limited | Current |
| Higher Pharmatech Private Limited | Previous |
Associated Brands with Instapill Private Limited
Instapill Private Limited operates two associated brands: Triphase Pharmaceuticals and Tenshi Life Sciences. These brands represent Instapill Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Offers comprehensive solutions in probiotic products, animal nutrition, and ingredients. | triphasepharma.com | |
| Delivers advanced finished dosage pharmaceuticals using global infrastructure and quality systems. | tenshi.co.in |
Competitors & Alternatives of Instapill Private Limited
Brands and companies operating in the same space as Instapill Private Limited include The Good Bug, Pendulum, Concord Biotech and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
The Good Bug
|
Synbiotic supplements and fermented products for gut health are provided. | Mumbai, India, India | 2021 |
Pendulum
|
Pendulum is focused on developing advanced probiotic solutions. | San Francisco, United States, United States | 2012 |
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
OptiBiotix Health
|
Microbial strains are developed for treating human metabolic diseases. | York, United Kingdom, United Kingdom | 2012 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Aurobindo Pharma
|
Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Business Activity of Instapill Private Limited
Instapill Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Instapill Private Limited
Instapill Private Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Deloitte Haskins & Sells LLP | blur-value | blur-value | blur-value |
Board of Directors of Instapill Private Limited
Instapill Private Limited is currently managed by 7 directors, with 13 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Ankit Gupta
Also directs:
Ai Cue Capital Llp, Dvise Medtech Private Limited, Karuna Healthcare Group Private Limited and 2 more
|
Whole-Time Director | 11 Feb 2025 | 1 Years 5 Months | Current |
|
Venkataraman Subramanian Iyer
Also directs:
Areco Leafware Llp
|
Director | 02 Apr 2007 | 19 Years 3 Months | Current |
|
Rajashri Santosh Kumar Ojha
Also directs:
Fermenta Biotech Limited, Raaj Gprac Private Limited
|
Director | 11 Feb 2025 | 1 Years 5 Months | Current |
|
Gopakumar Gopalan Nair
Also directs:
Gnanlex Associates Llp, Gnanlex Hermeneutics Private Limited
|
Director | 11 Feb 2025 | 1 Years 5 Months | Current |
| Guruswamy Pendyala | Whole-Time Director | 28 Apr 2017 | 9 Years 2 Months | Current |
Financials of Instapill Private Limited FY 2025 filings available
Instapill Private Limited reported revenue of ₹100.92 Cr (up 11% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Instapill Private Limited
As of FY 2024, Instapill Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Instapill Private Limited
Instapill Private Limited has 2 associated companies. This group structure data is as of FY 2024. The corporate group structure reflects Instapill Private Limited's business expansion strategy and organizational complexity.
Charges & Borrowings of Instapill Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Oct 2025 | Others | ₹60 Cr | Open |
| 13 Oct 2025 | Others | ₹95 Cr | Open |
| 09 Oct 2025 | Others | ₹10 Cr | Open |
| 22 Jul 2025 | Hdfc Bank Limited | ₹32.21 Lakh | Open |
| 24 May 2024 | Hdfc Bank Limited | ₹26.81 Lakh | Open |
Total charge records: 14 View all charges
Employees and EPFO Compliance at Instapill Private Limited
Instapill Private Limited has a workforce of 161 employees as of Aug 07, 2024.
Employee Count & EPFO Data of Instapill Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Instapill Private Limited
GSTIN & GST Filing Data of Instapill Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Instapill Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Instapill Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Instapill Private Limited
MSME Payment Delays by Instapill Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Instapill Private Limited
Subsidiaries & Group Companies of Instapill Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Instapill Private Limited with ownership details.
MCA Filings & Documents of Instapill Private Limited
MCA Filings & Documents of Instapill Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Instapill Private Limited
Recent News on Instapill Private Limited
Frequently Asked Questions about Instapill Private Limited
Instapill Private Limited is an active private limited company in the pharma sector based in Bangalore, Karnataka, India. It was incorporated on 02 April 2007 (19+ years old) and is registered under CIN U24230KA2007PTC042337. The company has 161 employees.
Instapill Private Limited reported revenue of ₹100.92 Cr for FY 2025 (up 11.00% YoY).
The current directors of Instapill Private Limited are:
- Ankit Gupta
- Venkataraman Subramanian Iyer
- Rajashri Santosh Kumar Ojha
- Gopakumar Gopalan Nair
- Guruswamy Pendyala
- Ankit Gupta
- Gunashekar Karthik
The primary industry of Instapill Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Instapill Private Limited can be reached at the registered office: Plot No 46 1St Phase Kiadb Industrial Area Harohalli Kanakapura, Bangalore, Karnataka, India – 562112, or through the website tenshi.co.in.
The authorised capital is ₹25.58 Cr, and the paid-up capital is ₹18.64 Cr.